Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2529)	10/13/2018 11:46:07 AM
From: Miljenko Zuanic	Respond to of 3559

To be honest I do not understand this trial (with Fasinumab) at all? Are they investigating off-target effects as potential SAE generator/potentiate, or something that can "damage" peripheral nerve function and reduce pain intensity (due to signal lost), as positive? Anyway, I thought that Teva (after internal/financial problems) will dump program and give back candidate right...contrary, they continue to "waste" sources. How can REGN be that persuasive and keep they in line???